aktiencheck.de - Forum - Hana Biosciences old

Kommt bei Hana Bioscience ein möglicher Rebound?

TLON, bekommt finanzierung ANNOUNCEMENT TLON Talon Therapeutics Announces $11M Financing SAN MATEO, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc., (OTCBB:TLON), today announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management, its largest shareholders, for the sale of $11 million in preferred stock. Talon intends to use the net proceeds from the financing to advance its clinical development and regulatory activities for Marqibo®, and for general corporate purposes. The Investment Agreement provides an option for the investors to purchase up to an additional $60M in preferred stock within one year following an accelerated approval of Marqibo. "We are pleased Warburg Pincus and Deerfield continue to support the Company's initiatives. This $11 million will primarily fund our efforts to obtain FDA approval for Marqibo, which has a PDUFA date of May 13, 2012. The potential for subsequent cash infusions from this financi [mehr]

Hana Biosciences Inc A0ETGH

EU-Behörde verleiht Marqibo Orphan-Drug-Status, Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia SOUTH SAN FRANCISCO, Calif., July 14, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the European Commission has granted orphan medical product designation to Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) for the treatment of adult acute lymphoblastic leukemia (ALL). This designation was granted based on the recommendation of the European Medicines Evaluation Agency (EMEA) following a positive opinion from the Committee for Orphan Medicinal Products. Orphan designation in the European Union offers significant benefits to Hana Biosciences, including market exclusivity for a period of ten years, financial incentives such as fee reductions or exemptions, EMEA scientific advice on p [mehr]

Hana Biosciences:Eine große Story nimmt ihren Lauf

rt 1,73, bald 1,0€ oder 0,01 cent [mehr]

So viel zu Hana

Gehts noch etwas "Blöder" ??, """Somit ist das Ask ja schon 0,23€ höher als vorhin bei meinem Kauf!:-) """ Ja und ein 20 Euro Schein ist schon schon 200 % mehr wert als mein Kauf der Hana. Der macht sich doch nun immer mehr zum Affen oder wie seht ihr das? Betrüger/Lügner/Abzocker darf ich ihn ja nicht mehr benennen denn sonst werde ich wieder gesperrt. :-))) Aber was ich weiter denke das kann man sich nun an 3 Fingern abzählen. [mehr]